Medicine, Health Care<\/a> New Study Offers Novel Treatment\u2026<\/a> <\/a><\/a><\/a><\/a><\/p>\n
Published: September 21, 2017.
Released by Boston University School of Medicine<\/a>\u00a0\u00a0<\/a><\/p>\n
(Boston) – Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide.<\/p>\n
In a new study, researchers demonstrate for the first time that a previously uncharacterized protein is increased in colon cancer. The protein is immunoglobulin containing proline rich receptor-1 (IGPR-1) which was recently identified in the same laboratory as a cell adhesion molecule.<\/p>\n
The new findings, reported online in Oncogenesis<\/em>, shed light on how IGPR-1 contribute to colon tumor growth and drug resistance.<\/p>\n To grow and survive, normal cells needs to attach to extracellular matrix (ECM). However, cancerous cells, often bypass this requirement and instead they rely on cell-cell adhesion for survival and growth. By manipulating IGPR-1 expression in colon cancer tumor, the scientists revealed that IGPR-1 by promoting tumor cell-cell adhesion plays a critical role in colon cancer. The researchers hope to propose a new treatment strategy for patients with colon cancer.<\/p>\n “We demonstrate that IGPR-1 by promoting tumor cell-cell adhesion stimulates tumor growth in cell culture and in an experimental model. Blocking IGPR-1 by a specific blocking antibody and shRNA inhibited tumor growth, suggesting a significant therapeutic potential for targeting IGPR-1 in colorectal cancer ” explained corresponding author Nader Rahimi, PhD, associate professor of pathology laboratory Medicine at Boston University School of Medicine.<\/p>\n The researchers also demonstrated that IGPR-1 determines the sensitivity of tumor cells to chemotherapeutic agent, doxorubicin\/Adriamycin and identified the mechanism by which IGPR-1 contributes to drug resistance in colon cancer, a major challenge associated with the treatment of this cancer.<\/p>\n Medicine, Health Care New Study Offers Novel Treatment\u2026 Published: September 21, 2017.Released by Boston University School of Medicine\u00a0\u00a0 (Boston) – Colorectal cancer is the fourth leading cause of cancer-related deaths worldwide. In a new study, researchers demonstrate for the first time that a previously uncharacterized protein is increased in colon cancer. The protein is immunoglobulin […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-85053","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/posts\/85053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/comments?post=85053"}],"version-history":[{"count":0,"href":"https:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/posts\/85053\/revisions"}],"wp:attachment":[{"href":"https:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/media?parent=85053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/categories?post=85053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthmedicinet.com\/news\/wp-json\/wp\/v2\/tags?post=85053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Chinese<\/a>\u00a0French<\/a>\u00a0German<\/a>\u00a0Italian<\/a>\u00a0Japanese<\/a>\u00a0Korean<\/a>\u00a0Portuguese<\/a>\u00a0Russian<\/a>\u00a0Spanish<\/a><\/p>\n\n","protected":false},"excerpt":{"rendered":"